1TMDX Stock Overview

A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More details

1TMDX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 27.4% below our estimate of its fair value

Earnings are forecast to grow 27.56% per year

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

High level of non-cash earnings

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

TransMedics Group, Inc. Competitors

DiaSorin

BIT:DIA

€5.2b

EL.En

BIT:ELN

€729.1m

Amplifon

BIT:AMP

€4.3b

I.M.D. International Medical Devices

BIT:IMD

€24.6m

Price History & Performance

Summary of share price highs, lows and changes for TransMedics Group
Historical stock prices
Current Share Price	US$82.76
52 Week High	US$0
52 Week Low	US$0
Beta	1.9
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-0.22%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1TMDX	IT Medical Equipment	IT Market
7D	3.7%	-0.009%	2.1%
1Y	n/a	0.9%	12.2%

Return vs Industry: Insufficient data to determine how 1TMDX performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1TMDX performed against the Italian Market.

Price Volatility

Is 1TMDX's price volatile compared to industry and market?
1TMDX volatility
1TMDX Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.1%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1TMDX's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1TMDX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	728	Waleed Hassanein	www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.

TransMedics Group, Inc. Fundamentals Summary

How do TransMedics Group's earnings and revenue compare to its market cap?
1TMDX fundamental statistics
Market cap	€2.79b
Earnings (TTM)	€31.35m
Revenue (TTM)	€390.32m

91.4x

P/E Ratio

7.3x

P/S Ratio

Is 1TMDX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1TMDX income statement (TTM)
Revenue	US$441.54m
Cost of Revenue	US$179.46m
Gross Profit	US$262.08m
Other Expenses	US$226.62m
Earnings	US$35.46m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)	1.05
Gross Margin	59.36%
Net Profit Margin	8.03%
Debt/Equity Ratio	222.8%

How did 1TMDX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 00:28
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TransMedics Group, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Rescott	Baird
William Plovanic	Canaccord Genuity
K. Gong	J.P. Morgan